CYAD-101

Phase 1Small molecule

CCelyad Oncology SA

CYAD-101 is one of 48 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerRecruiting

Chimeric Antigen Receptor T-CellRecruiting

Metastatic Colorectal CancerPhase 1

Recruiting

Chimeric Antigen Receptor T-CellPhase 1

Recruiting

Competition

Competitive Landscape

144 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

20 2

Opdivo

Bristol-Myers Squibb

Phase 3

13 3

Braftovi

Pfizer

Phase 3

11 4

Tecentriq

Roche

Phase 3

10 5

FOLFIRI

Amgen

Phase 3

36 6

Yervoy

Bristol-Myers Squibb

Phase 3

7 7

Bayer Aspirin

Bayer

Phase 3

2 8

Folinic Acid

Roche

Phase 3

17 9

Lumakras

Amgen

Phase 3

1 10

FOLFOX

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2036

Phase 1Recruiting

Chimeric Antigen Receptor T-Cell

NCT03692429

Q2 2038

Phase 1Recruiting

Metastatic Colorectal Cancer

NCT04991948

Clinical

Trials by Indication[1]

Chimeric Antigen Receptor T-cell1 trial

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Recruiting·CCelyad Oncology SA·Phase 1·NCT03692429·49 enrolled

Metastatic Colorectal Cancer1 trial

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Recruiting·CCelyad Oncology SA·Phase 1·NCT04991948·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CYAD-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CYAD-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CYAD-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celyad Oncology SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCelyad Oncology SA

CYAD-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2036

Q2 2038

Trials by Indication[1]

Chimeric Antigen Receptor T-cell1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News